

Curriculum Vitae

Name in Full Jin-Hyoung Kang, M.D. Ph.D. (no. 27247)
Office Address Division of Medical Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Korea, 06591.

Present Academic & Hospital Appointments

Professor, Division Chief
Division of Medical Oncology
Department of Internal Medicine
Seoul St. Mary's Hospital
The Catholic University of Korea

Education

Mar. 1978 - Feb. 1984 Graduated from The Catholic University of Korea in Seoul, Korea
Mar. 1986 - Feb. 1988 Earned Master's Degree from The Catholic University Graduate School in Seoul, Korea
Sep. 1991 - Feb. 1995 Earned Ph. D. from The Catholic University Graduate School in Seoul, Korea
Mar. 2016 - Feb. 2018 Executive MBA, Korea University Business School, Korea

Professional Experiences

Mar. 1984 - Feb. 1985 Internship in St. Mary's Hospital
Mar. 1985 - Feb. 1988 Residency of Internal Medicine in St. Mary's Hospital
Feb. 1988 Korean Board of Internal Medicine
Mar. 1988 - Apr. 1991 Served in Korean Army as the Army Physician
May 1991 - Feb. 1993 Trained as Clinical Fellow, Division of Hemato-Oncology, Department of Internal Medicine in Kangnam St. Mary's Hospital, Seoul, Korea
Mar. 1993 - Feb. 1995 Worked as Instructor, Division of Hemato-Oncology, Department of Internal Medicine in Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Mar. 1995 - Aug. 1999 Worked as Assistant Professor, Division of Hemato-Oncology, Department of Internal Medicine in St. Vincent Hospital, The Catholic University of Korea, Suwon, Korea
Feb. 1996 - Apr. 1998 Worked as Research Fellow, Division of Hemato-Oncology Department of Medicine, Cornell University Medical College New York, N.Y. USA
Sep. 1999 - Mar. 2004 Worked as Associate Professor, Division of Medical Oncology, Department of Internal Medicine in Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Apr. 2004 - Working as Professor, Division of Medical Oncology, Department of Internal Medicine in Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Mar. 2006 - Division Chief in Medical Oncology
Mar. 2009 - Deputy Director of Catholic Cancer Center
Sep. 2011 - Team Leader of Lung Cancer Multidisciplinary Team, The Catholic Cancer Center
Mar, 2016- President of Korean Cancer Study Group

Membership

The Korean Medical Association
The Korean Society of Internal Medicine
The Korean Cancer Association
Korean Cancer Study Group
Korean Association for Clinical Oncology
The Korean Society of Head & Neck Cancer
International Association for the Study of Lung Cancer
The American Association for Cancer Research
The American Society of Clinical Oncology
Korean Cancer Foundation

Award

Grant projects involved in over the last 5 years

Grant titles in clinical field:

- A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (2016.07.01-2021.04.24)
- An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2016.11.01 – 2020.01.31)
- Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy (2017.03.05 – 2023.08.31)
- An Open label, Multicenter, Phase II study of AZD9291 in non-small cell lung cancer (NSCLC) patients harboring T790M mutation who failed EGFR TKIs and with brain and/or leptomeningeal metastasis (2017.08.16-2019.12.31)
- An Open- Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer(2017.01.29)
- A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib(2017.12.19-2020.04.30)
- ONO-4538 Phase 3 Study, A Multicenter, Randomized, Double-Blind Trial in Subjects with Non-Squamous Non-Small Cell Lung Cancer(2017.09.14-2022.07.31)
- Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer(NSCLC), Who Have Been Previously Treated with EGFR tyrosine kinase receptor (TKI) therapy; KOREA study (Korea Osimertinib Real world Evidence study to Assess safety and efficacy)(2017.07.25-2020.03.31)
- A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma(2019.09.22-2021.06.30)
- The Effect of EGFR TKI Treatment Based on Liquid Biopsy Panel Screening in Patients with Non-Small Cell Lung Cancer(2018.02.20-2021.12.31)
- A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)(2017.06.23-2019.12.31)
- A randomized, open-label study of combinations of standard and high dose REGN2810(cemiplimab: anti-PD-1 antibody) and ipilimumab(anti-CTLA-4 antibody) in the second-line treatment of patients with advanced non-small cell lung cancer(2018.06.15-2022.04.13)
- A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (Erlotinib or Gefitinib), as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis(2018.09.14-2020.06.30)
- A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)(2018.12.31-2020.04.28)
- A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).(2018.03.29-2022.12.31)
- A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)(2018.07.16-2023.09.18)
- A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)(2019.01.24-2025.03.31)
- A Retrospective Multicenter Study for Evaluation of Real-world Efficacy and Safety of Immune-checkpoint inhibitors (ICIs) in Patients with Advanced and/or Metastatic Non-small cell lung cancer (NSCLC)(2019.01.11-2019.12.31)
- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)(2019.02.12-2023.09.30)